role cancer immunotherapy arena cellular immunotherapy field study field strong foundations numerous animal tumor models avenues research refinements human immunotherapy Experience number research centers LAK cell trials humans PBMCs possess reproducible antitumor activity vitro Exogenous administration patients biologic activity activated cells requirement LAK cells tumors melanoma clear-cut Overall response rate humans toxicity immunotherapy dose systemic next generation trials cellular immunotherapy humans TILs Murine experiments population cells powerful specific tumor LAK cells LAK cells TILs exogenous optimum performance vivo difficulty reproducible TIL growth use monoclonal antibody activation Improvements TIL therapy use TILs hybrid antibodies addition biologic response modifiers implementation cells cell products 